Predicted protein targets (top 5)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KMT2A | Q03164 | 1/20 | 0.33 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.33 |
| ▸ | HTR2A | P28223 | 1/20 | 0.33 |
| ▸ | HTR2C | P28335 | 1/20 | 0.33 |
| ▸ | HTR2B | P41595 | 1/20 | 0.33 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4079547 | 0.81 | SCN5A (0.37) | KMT2ASMN1; SMN2HTR2AHTR2B | |
| SCHEMBL4073220 | 0.79 | MET (0.32) | — | |
| SCHEMBL4073326 | 0.76 | HTR1A (0.38) | — | |
| SCHEMBL4072447 | 0.74 | MRGPRX4 (0.35) | — | |
| SCHEMBL4073841 | 0.71 | SMN1; SMN2 (0.49) | KMT2ASMN1; SMN2 | |
| SCHEMBL2340708 | 0.70 | ALDH1A1 (0.42) | HTR2AHTR2CHTR2B | |
| SCHEMBL768553 | 0.70 | KMT2A (0.61) | KMT2ASMN1; SMN2HTR2AHTR2CHTR2B | |
| SCHEMBL768552 | 0.70 | KMT2A (0.61) | KMT2ASMN1; SMN2HTR2AHTR2CHTR2B | |
| SCHEMBL27687450 | 0.68 | HTR2A (0.33) | HTR2AHTR2CHTR2B | |
| SCHEMBL4219545 | 0.67 | HTR2A (0.35) | HTR2AHTR2CHTR2B |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2066673-A2 | TRICYCLIC COMPOUNDS AND ITS USE AS TYROSINE KINASE MODULATORS | ChemBridge Research Laboratories, Inc. (US) | 2009-06-10 | — | — | EP | disclosed |
| WO-2008021369-A2 | TRICYCLIC COMPOUNDS AND ITS USE AS TYROSINE KINASE MODULATORS | CHEMBRIDGE RESEARCH LABORATORIES, INC. (US) | 2008-02-21 | — | — | WO | disclosed |